Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-24 in Adults With Down Syndrome
NCT04373616Phase 2Withdrawn
- Sponsor
- AC Immune SA
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of ACI-24 in Alzheimer's disease (AD), sponsored by AC Immune SA. Planned start Oct 2021; status: withdrawn.
02
Drugs
ACI-24
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04373616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373616.